Drug levels after sirolimus initiation and short‐term outcomes in ambulatory heart transplantation recipients

Abstract

AbstractIntroductionWe evaluated the effect of relative changes in combined tacrolimus and sirolimus (drug) levels, following sirolimus initiation, on outcomes in ambulatory heart transplantation (HTx) recipients.MethodsWe performed a retrospective analysis of HTx recipients who received tacrolimus, followed by sirolimus initiation, any time after HTx. We calculated the relative change in combined drug levels 1‐month post‐sirolimus initiation, relative to tacrolimus levels pre‐initiation, and categorized patients into decreased (≥15% decrease), stable (<15% decrease to <15% increase), or increased (≥15% increase) groups. We compared, across the three groups, changes in post‐initiation estimated glomerular filtration rate (eGFR) and left ventricular ejection fraction (LVEF) using one‐way ANOVA and Šidák's post‐hoc analysis, as well as the individual and composite outcomes of new donor specific antibodies (DSA), acute cellular rejection (ACR), and all‐cause mortality using Fisher's exact test.ResultsAmongst 99 HTx recipients included, the median age was 53 years, time to sirolimus initiation was 1.5 years post‐HTx, and pre‐sirolimus eGFR was 52 mL/min/1.73 m2. Nine patients had decreased, 15 stable, and 75 increased, relative combined drug levels. Relative change in eGFR was significantly higher in patients with decreased levels compared to patients with increased levels at 6 months post‐initiation (P < .05), but this was not sustained at 12 months. There were no differences in LVEF change or in individual and composite risks for developing DSA, ACR, and all‐cause mortality at 12 months across the groups.ConclusionPost‐sirolimus initiation, a relative decrease in combined drug levels, compared to increased levels, was associated with temporarily improved renal function.